Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02853604 · ClinicalTrials.gov registry record · Phase 3
Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer
A Phase 3 study, sponsored by Advaxis.
- Terminated
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT02853604: Clinical Trial Phase 3 study, sponsored by Advaxis.
NCT02853604 is a Phase 3 study that was terminated before completion, run by Advaxis. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02853604, a Phase 3 study, was terminated before completion, sponsored by Advaxis.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosis is very grave for those who experience a recurrence. The purpose of the study was to compare the disease free survival (DFS) of ADXS11-001 to placebo administered following cisplatin-based combination chemotherapy and radiation (CCRT) with curative intent in participants with HRLACC.
Interventions
- DRUG Placebo
- DRUG ADXS11-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-12-15 |
| Est. Completion | 2019-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02853604
The ClinicalTrials.gov registry entry for NCT02853604 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advaxis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02853604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02853604 about?
NCT02853604 is a clinical study titled "Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer". Locally advanced cervical cancer at higher risk for recurrence (HRLACC) following concurrent chemotherapy and radiation therapy. This is a group of participants with a significant unmet need. The estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and the prognosi...
What is the current status of trial NCT02853604?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2015-12-15. Estimated completion is 2019-07-31.
What interventions are being tested in trial NCT02853604?
The interventions under investigation include: Placebo (DRUG), ADXS11-001 (DRUG).
Who is sponsoring clinical trial NCT02853604?
This trial is sponsored by Advaxis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.